0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover186.10%IV-63.15%PremiumJan 17, 2025Expiry Date8.57Intrinsic Value100Multiplier21DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9926Delta0.0033Gamma1.58Leverage Ratio-0.0034Theta0.0029Rho1.57Eff Leverage0.0007Vega
Eton Pharmaceutical Stock Discussion
just
Eton Pharmaceuticals Closes Acquisition of Increlex® (Mecasermin Injection)
Benzinga· 5 mins ago1min
The study demonstrated that PKU GOLIKE, administered as the last daily dose and compared to standard amino acid protein substitutes, improved metabolic control by reducing harmful phenylalanine (Phe) levels and increasing beneficial tyrosine (Tyr) levels,...
Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)
Eton Pharmaceuticals has acquired U.S. rights to Amglidia (glyburide oral suspension) from AMMTeK for treating neonatal diabetes mellitus.
The product, already approved by the European Medicines Agency since 2018, has received Orphan Drug Designation from the FDA. Amglidia is a patented liquid formulation targeting approximately 300 U.S. patients with neonatal dia...
Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)
1 MINUTE AGO, 6:30 AM EDT
VIA GLOBENEWSWIRE
Aligns with Eton's Mission to Develop and Distribute Medicines that Have a Life Changing Impact for Patients with Ultra-rare Conditions
Acquisition to Bolster Eton's Commercial Pediatric Endocrinology Portfolio! Transaction Financed by Eton's Cash and Expanded Credit Facility
No comment yet